R162 (64302-87-0) is a selective inhibitor of Glutamate Dehydrogenase 1 (Ki = 28.6 µM), a commonly upregulated enzyme in human cancers. It does not inhibit the activity of other NADPH enzymes such as 6-phosphogluconate dehydrogenase and fumarate hydratase. R162 treatment lead to decreased fumarate levels, lower glutathione peroxidase activity, increased ROS levels and reduced cell proliferation in H1299 and MDA-MB231 cells.
1) Lingtao et al. (2015), Glutamate Dehydrogenase 1 Signals through Antioxidant Glutathione Peroxidase 1 to Regulate Redox Homeostasis and Tumor Growth; Cancer Cell, 27 257